News
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis meldet bedeutenden Erfolg der klinischen Phase-II-Studie HEART: die patentgeschützte pflanzenbasierte aktive Substanz TOTUM•070 zeigt Wirksamkeit gegen Hypercholesterinämie, einen kardiovaskulären Risikofaktor
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel- und
Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Bryan Garnier & Co Initiates the Coverage of Median Technologies with a “Buy” Recommendation
Regulatory News:
Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies.
In the
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies to Present an Abstract at the 2022 ASCO Annual Meeting, June 3 – 7, 2022, McCormick Place, Chicago, IL, USA
Regulatory News:
Median Technologies (ALMDT) announced today that it will be presenting an abstract at the 2022 ASCO Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates
MYHOTELMATCH accelerates growth by acquiring premium concierge group My Agency
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials
Regulatory News:
Median Technologies (Paris:ALMDT) announces that the company is expanding its portfolio of services with Imaging Lab, a new entity whose mission is to leverage AI, data mining
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022
Regulatory News:
The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal
MYHOTELMATCH: Authorisation of the Commercial Court to postpone the General Meeting
Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
BILENDI: Q1 2022 revenues: €13.4 million, up +52% (+13.7% on a pro forma basis)
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies Is Moving Forward With the FDA Interactions for Its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Regulatory News:
Median Technologies (ALMDT) announces today that the company has received feedback from the United States Food and Drug Administration (FDA) regarding the 513(g) submission done
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
ROCTOOL INNOVATES WITH THE CEA - Presentation of lightweight, 3D and eco-friendly solar panels at JEC and Intersolar
Valbiotis gibt den ersten Besuch des ersten Patienten in der von der INAF1 in Partnerschaft mit Nestlé Health Science durchgeführten klinischen Studie zur Wirkungsweise von TOTUM•63 bekannt
Regulatorische Nachrichten:
Valbiotis (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und